(UroToday.com) Urothelial carcinoma has a substantial impact on patient qualify of life. Patients may experience a multitude of disease-related symptoms, including pain, urinary frequency, physical changes, and mental health issues, with all affect quality of life. Additionally, treatment side effects of chemotherapy have been shown to reduce the quality of life in patients with advanced urothelial carcinoma. In the phase III JAVELIN Bladder 100 trial, avelumab (anti–PD-L1) first-line maintenance plus best supportive care significantly prolonged overall survival (primary endpoint) versus best supportive care alone in patients with advanced urothelial carcinoma without disease progression with first-line induction chemotherapy (HR 0.69, 95% CI 0.56-0.86).1 At the European Society of Medical Oncology (ESMO) 2020 Virtual Congress, Dr. Thomas Powles and colleagues reported patient-reported outcomes from the JAVELIN Bladder 100 study.